|
Post by mnkdnut on Nov 6, 2015 3:17:23 GMT -5
Lixilan, Toujeo and now, Hanmi, seem to have pushed Afrezza to the sideline in Brandicourt's eyes. The way they are approaching Praluent is what we were expecting for Afrezza, but instead we get left out. Their position on A must be in flux or under internal discussion. Extremely disappointing to say the least.....
|
|
hd99
Newbie
Posts: 18
|
Post by hd99 on Nov 6, 2015 3:21:58 GMT -5
|
|
|
Post by mnkdorbust on Nov 6, 2015 3:22:41 GMT -5
|
|
hd99
Newbie
Posts: 18
|
Post by hd99 on Nov 6, 2015 3:24:09 GMT -5
page 105 !
|
|
hd99
Newbie
Posts: 18
|
Post by hd99 on Nov 6, 2015 3:24:48 GMT -5
Time needed for Afrezza® to demonstrate its potential ● Gradual market access ● FDA requirements for starting patients on Afrezza® ● Novel mode of administration and innovative nature of the product
|
|
|
Post by mnkdorbust on Nov 6, 2015 3:26:26 GMT -5
Afrezza is mentioned on slide 24
|
|
|
Post by boytroy88 on Nov 6, 2015 3:26:43 GMT -5
Time needed for Afrezza® to demonstrate its potential ● Gradual market access ● FDA requirements for starting patients on Afrezza® ● Novel mode of administration and innovative nature of the product Wow...you scan fast! Thx!
|
|
hd99
Newbie
Posts: 18
|
Post by hd99 on Nov 6, 2015 3:27:28 GMT -5
|
|
|
Post by benyiju on Nov 6, 2015 3:27:42 GMT -5
Dieu merci!
|
|
|
Post by jpg on Nov 6, 2015 3:30:16 GMT -5
OK slightly reassuring. Slightly...
|
|
hd99
Newbie
Posts: 18
|
Post by hd99 on Nov 6, 2015 3:34:15 GMT -5
|
|
|
Post by benyiju on Nov 6, 2015 3:34:48 GMT -5
allez, courage!
|
|
|
Post by chuck on Nov 6, 2015 3:36:08 GMT -5
They cut the target market in half. Down from 2 million to 1 million.
|
|
|
Post by blindhog1 on Nov 6, 2015 3:37:23 GMT -5
We aren't on the top of the heap, but we are included in the mix. Sanofi is more than restructuring itself. Monday with MNKD will be more telling. We all know Sanofi has a full plate.
|
|
|
Post by benyiju on Nov 6, 2015 3:40:27 GMT -5
Ne te laisse pas abattre! Seriously, wait for script #s.
|
|